1. Search Result
Search Result
Results for "

Microtubule inhibition

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

2

Fluorescent Dyes

1

Inhibitory Antibodies

4

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-N0282
    Demecolcine
    5+ Cited Publications

    Microtubule/Tubulin Apoptosis Inflammation/Immunology Cancer
    Demecolcine is a potent mitotic inhibitor with an IC50 value of 2.4 μM for inhibition of tubulin polymerization. Colcemid (Demecolcine) can interact with tubulin dimers to induce anti-mitotic action and inhibit microtubule growth. Colcemid (Demecolcine) can be used for inflammatory disorders and cancer research .
    Demecolcine
  • HY-P99016B
    Enfortumab vedotin-ejfv (solution)
    1 Publications Verification

    Antibody-Drug Conjugates (ADCs) Nectin-4 Cancer
    Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
    Enfortumab vedotin-ejfv (solution)
  • HY-P99016A
    Enfortumab vedotin-ejfv
    1 Publications Verification

    Antibody-Drug Conjugates (ADCs) Nectin-4 Cancer
    Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
    Enfortumab vedotin-ejfv
  • HY-B0294
    Flubendazole
    Maximum Cited Publications
    8 Publications Verification

    Parasite Microtubule/Tubulin STAT MDM-2/p53 Apoptosis Autophagy Infection Cancer
    Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites .
    Flubendazole
  • HY-W011102
    S-Trityl-L-cysteine
    2 Publications Verification

    NSC 83265; S-Tritylcysteine; 3-Tritylthio-L-alanine

    Kinesin Apoptosis Cancer
    S-Trityl-L-cysteine (NSC 83265) is a selective and allosteric kinesin Eg5 inhibitor with an IC50 of 1 μM for the inhibition of basal ATPase activity and 140 nM for the microtubule-activated ATPase activity. S-Trityl-L-cysteine has antitumor activities .
    S-Trityl-L-cysteine
  • HY-N1408

    trans-trismethoxy Resveratrol; (E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene

    VEGFR Reactive Oxygen Species (ROS) Caspase Apoptosis Inflammation/Immunology Cancer
    Trans-Trimethoxyresveratrol (trans-trismethoxy Resveratrol; (E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene) is an orally active natural derivative of Resveratrol (HY-16561). Trans-Trimethoxyresveratrol has an enhanced anticancer profile compared to Resveratrol, exhibiting higher potency than resveratrol, with improved cancer cell proliferation inhibition, induction of cell cycle arrest, decreased metastasis, and increased apoptosis. Trans-Trimethoxyresveratrol causes microtubule disassembling and tubulin depolymerization and exerts anti-angiogenic effects through VEGFR2. Trans-Trimethoxyresveratrol can be used for the studies of anti-angiogenic and anti-cancer (such as non-small cell lung cancer and osteosarcoma) .
    trans-Trimethoxyresveratrol
  • HY-B0294S

    Parasite Microtubule/Tubulin Apoptosis Infection Cancer
    Flubendazole-d3 is the deuterium labeled Flubendazole. Flubendazole is a safe and efficacious anthelmintic agent, which is widely used for anthelmintic to human, rodents and ruminants. Flubendazole exerts anticancer activities by mechanisms including inhibition of microtubule function. Flubendazole induces p53-mediated apoptosis and arrests G2/M cell cycle .
    Flubendazole-d3
  • HY-N3225

    NAMPT Sirtuin Microtubule/Tubulin Apoptosis Autophagy PDGFR NF-κB AMPK Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Myricanol is a diarylheptanoid and a Nampt activator. Myricanol exerts anti-inflammatory effects and alleviates glucocorticoid-induced muscle atrophy by increasing Sirtuin 1 (SIRT1) and PRDX5 activities while regulating inflammatory factors. Myricanol exhibits growth inhibition and induces apoptosis in human lung adenocarcinoma A549 cells. Myricanol promotes autophagy-mediated clearance of microtubule-associated protein tau to exert neuroprotective effects. Myricanol protects cardiovascular function by inhibiting PDGFRβ and NF-κB signaling pathways. Myricanol activates mitochondrial transcription factor A (TFAM) expression to exert anti-renal fibrosis effects. Myricanol improves insulin resistance through AMPK activation .
    Myricanol
  • HY-N0282R

    Reference Standards Microtubule/Tubulin Apoptosis Inflammation/Immunology Cancer
    Colcemid (Standard) is the analytical standard of Colcemid. This product is intended for research and analytical applications. Colcemid (Demecolcine) is a potent mitotic inhibitor with an IC50 value of 2.4 μM for inhibition of tubulin polymerization. Colcemid (Demecolcine) can interact with tubulin dimers to induce anti-mitotic action and inhibit microtubule growth. Colcemid (Demecolcine) can be used for inflammatory disorders and cancer research .
    Colcemid (Standard)
  • HY-148542

    SD-142

    Endogenous Metabolite Cardiovascular Disease Cancer
    EpoY (SD-142) acts as an irreversible inhibitor of the brain's primary tubulin tyrosine carboxypeptidase (TCP), a complex formed by vasohibin-1 (VASH1) and the small vasohibin binding protein (SVBP). By inhibiting TCP with an IC50 value of approximately 500 nM, EpoY effectively decreases levels of detyrosinated alpha-tubulin, which is crucial for microtubule dynamics and neuronal differentiation. This inhibition leads to significant differentiation defects and has been linked to underlying issues associated with cancer and cardiomyopathies.
    EpoY
  • HY-103257

    NSC656158

    Microtubule/Tubulin Cancer
    CHM-1, a microtubule-destabilizing agent, inhibits tubulin polymerization. CHM-1 is a potent and selective antimitotic antitumor activity against human hepatocellular carcinoma. CHM-1 induces growth inhibition and apoptosis via G2-M phase arrest in human hepatocellular carcinoma cells by activation of Cdc2 kinase activity .
    CHM-1
  • HY-B0294R

    Reference Standards Parasite Microtubule/Tubulin STAT MDM-2/p53 Apoptosis Autophagy Infection Cancer
    Flubendazole (Standard) is the analytical standard of Flubendazole. This product is intended for research and analytical applications. Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites .
    Flubendazole (Standard)
  • HY-178441

    Pyruvate Kinase Reactive Oxygen Species (ROS) Apoptosis Microtubule/Tubulin Metabolic Disease Cancer
    PKM2-IN-11 is a PKM2 inhibitor (IC50 = 0.363 μM). PKM2-IN-11 has dual mechanisms involving pyruvate kinase M2 (PKM2) inhibition and microtubule stabilization. PKM2-IN-11 can decrease PKM2 protein levels in MCF-7 cells. PKM2-IN-11 can slightly reduce reactive oxygen species (ROS) levels and significantly increase early apoptotic cells. PKM2-IN-11 induces G2/M phase arrest. PKM2-IN-11 can be used for the study of breast cancer .
    PKM2-IN-11
  • HY-147725

    Microtubule/Tubulin Cancer
    Microtubule inhibitor 4 (compound 2) is a potent microtubule inhibitor. Microtubule inhibitor 4 shows cytotoxicity with IC50s of 4.0, 3.2, 2.1 nM for NCI-H460, BxPC-3, HT-29 cells, respectively. Microtubule inhibitor 4 shows the inhibition of tubulin polymerization .
    Microtubule inhibitor 4
  • HY-121634

    Polo-like Kinase (PLK) Others
    DAP-81 is an inhibitory agent targeting Polo-like kinases (Plks), a class of evolutionarily conserved serine/threonine kinases. DAP-81 dose-dependently increases the number of monopolar spindles in treated cells. High-resolution live-cell microscopy revealed that Plk activity is required for the assembly and maintenance of bipolar mitotic spindles. Plk inhibition destabilizes centromeric microtubules while stabilizing other spindle microtubules, leading to the formation of monopolar spindles. Further testing of compounds based on "privileged scaffolds" such as the DAP scaffold may lead to the discovery of new cell division probes and anti-microtubule agents.
    DAP-81
  • HY-105409

    NVP-XAA-296; XAA 296

    Microtubule/Tubulin Apoptosis Cancer
    Discodermolide (NVP-XAA-296) is a potent microtubule-stabilizing agent with a Ki of 0.4 μM. Discodermolide stabilizes microtubules, induces G2 or M phase cell cycle arrest and apoptosis, leading to inhibition of cancer cell proliferation. Discodermolide competitively inhibits the binding of Paclitaxel (HY-B0015) to tubulin polymers, and inhibits the growth of Paclitaxel-resistant cells. Discodermolide can be used for breast and colon cancer research .
    Discodermolide
  • HY-120599A

    VERU-111 hydrochloride; ABI-231 hydrochloride

    Microtubule/Tubulin Apoptosis HPV Endogenous Metabolite Cancer
    Sabizabulin hydrochloride is a potent orally bioavailable microtubule inhibitor with activity that interacts with the colchicine binding site. Sabizabulin hydrochloride demonstrated significant inhibition of melanoma tumor growth with an average IC50 of 5.2 nM in melanoma and prostate cancer cell lines. Pharmacological screening of Sabizabulin hydrochloride shows it has a low risk of potential side effects .
    Sabizabulin hydrochloride
  • HY-168128

    Microtubule/Tubulin Cancer
    Tubulin polymerization-IN-69 (compund 6c) significantly inhibits microtubule/tubulin polymerization in vitro (78.3% inhibition) with an IC50 value of 6.53 μM, and rapidly induces apoptotic cell death and G2/M cell cycle arrest in MCF-7 cells .
    Tubulin polymerization-IN-69
  • HY-13224A

    Endogenous Metabolite Cancer
    AZD4877 hydrochloride is a synthetic dynein inhibitor with potential anti-tumor activity. AZD4877 selectively inhibits the microtubule dynein KSP (also known as kinesin-5 or Eg5), which may lead to inhibition of mitotic spindle assembly. The action of AZD4877 may activate the spindle assembly checkpoint, leading to cell cycle arrest at the mitotic stage. AZD4877 may induce cell death in actively dividing tumor cells. AZD4877 may be less likely to cause peripheral neuropathy associated with microtubule-targeted compounds as it is not involved in post-mitotic processes. AZD4877 is essential for the formation of bipolar spindles and the proper segregation of sister chromosomes .
    AZD4877 hydrochloride
  • HY-161641

    Microtubule/Tubulin Cancer
    Tubulin polymerization-IN-62 (Compound 14b) is an inhibitor for microtubule polymerization (IC50 is 7.5 μM) and a degrader for α- and β-tubulin. Tubulin polymerization-IN-62 inhibits proliferation of cancer cells MCF-7, A549 and HCT-116, with IC50 of 32, 60 and 29 nM, respectively. Tubulin polymerization-IN-62 arrests the cell cycle at G2/M phase, inhibits the migration of MCF-7. Tubulin polymerization-IN-62 exhibits antitumor efficacy with a tumor growth inhibition rate (TGI) of 74.27% in 4T1 homograft mouse model .
    Tubulin polymerization-IN-62
  • HY-173182

    Microtubule/Tubulin P-glycoprotein Cancer
    Antitumor agent-200 (Compound 2g) is a microtubule synthesis inhibitor. By binding to the colchicine site of tubulin, it causes G2/M cell cycle arrest and generates reactive oxygen species (ROS). Antitumor agent-200 exhibits significant inhibitory activity against MCF7/ADR and KBV200 cell lines with overexpression of P-glycoprotein (P-gp), with drug resistance indices (DRI) of 0.83 and 0.58 respectively. In the MCF-7 xenograft model, Antitumor agent-200 (25 mg/kg, intraperitoneal injection) can achieve a tumor growth inhibition rate of 57.2%. Antitumor agent-200 can be used in the research of the anti-cancer field .
    Antitumor agent-200
  • HY-180147

    Microtubule/Tubulin Reactive Oxygen Species (ROS) Apoptosis Cancer
    Microtubule-IN-14 (Compound 10u) is a microtubule inhibitor. Microtubule-IN-14 inhibits the polymerization of tubulin, thereby preventing the formation of the spindle apparatus in cell mitosis and blocking the cell cycle at the G2/M phase. Microtubule-IN-14 induces a decrease in mitochondrial membrane potential and a burst of reactive oxygen species (ROS), promoting tumor cell apoptosis. Microtubule-IN-14 can be used for the study of non-small cell lung cancer and liver cancer .
    Microtubule-IN-14
  • HY-180148

    Microtubule/Tubulin Reactive Oxygen Species (ROS) Apoptosis Cancer
    Microtubule-IN-15 (Compound 10v) is a microtubule inhibitor. Microtubule-IN-15 inhibits the polymerization of tubulin, thereby preventing the formation of the spindle apparatus in cell mitosis and blocking the cell cycle at the G2/M phase. Microtubule-IN-15 induces a decrease in mitochondrial membrane potential and a burst of reactive oxygen species (ROS), promoting tumor cell apoptosis. Microtubule-IN-15 can be used for the study of non-small cell lung cancer and liver cancer .
    Microtubule-IN-15
  • HY-103257R

    NSC656158 (Standard)

    Reference Standards Microtubule/Tubulin Cancer
    CHM-1 (Standard) is the analytical standard of CHM-1 (HY-103257). This product is intended for research and analytical applications. CHM-1, a microtubule-destabilizing agent, inhibits tubulin polymerization. CHM-1 is a potent and selective antimitotic antitumor activity against human hepatocellular carcinoma. CHM-1 induces growth inhibition and apoptosis via G2-M phase arrest in human hepatocellular carcinoma cells by activation of Cdc2 kinase activity .
    CHM-1 (Standard)

온라인 문의

Your information is safe with us. * Required Fields.

호칭

 

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

 

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: